Second-line combination chemotherapy: A phase I study of ixabepilone, mitoxantrone, and prednisone in patients with metastatic hormone-refractory prostate cancer (HRPC) refractory to docetaxel-based therapy
2008 ◽
Vol 26
(15_suppl)
◽
pp. 5151-5151
◽
2006 ◽
Vol 42
(15)
◽
pp. 2530-2538
◽
2004 ◽
Vol 22
(14_suppl)
◽
pp. 2600-2600
◽
2004 ◽
Vol 22
(14_suppl)
◽
pp. 2600-2600